Other
ISS
0
Pipeline Programs↗
10
Active Trials↗
11
Companies Involved↗
ISS is an early-stage landscape with 0 programs across 11 companies. The most active players are AstraZeneca, Johnson & Johnson, GSK.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
83
clinical trials
Completed55 · 66%
Unknown status8 · 10%
Terminated5 · 6%
Withdrawn4 · 5%
Recruiting4 · 5%
Active, not recruiting3 · 4%
Other4 · 5%
Clinical Trials
Trial Activity
83 trials
The Effect of PAP on ISSHL Comorbided With OSA
Recruiting·—·Phase 4·NCT04192656·102 enrolled
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
Active, not recruiting·—·Phase 1·NCT03164486·27 enrolled
Retention Rate of Giomer Pit and Fissure Sealant Applied With or Without Etching
Active, not recruiting·—·Phase 4·NCT06509451·52 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)